Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in hiv-infected children treated with pediatric fixed-dose combination tablets

Therapeutic Drug Monitoring

Volumn 32, Issue 3, 2010, Pages 369-372

  Burger, David ^a   Ewings, Fiona ^b   Kabamba, Desiré ^c   L'Homme, Rafaëlla ^a   Mulenga, Veronica ^c   Kankasa, Chipepo ^c   Thomason, Margaret ^b   Gibb, Diana M ^b   Chintu, Chifumbe ^c   Walker, A Sarah ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY TEACHING HOSPITAL   (Zambia)

Author keywords

Children; Fixed dose combination; Limited sampling model; Pharmacokinetics; Predictive performance; Therapeutic drug monitoring

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE;

ACCURACY; ADOLESCENT; AFRICA; AREA UNDER THE CURVE; ARTICLE; CHILD; DRUG BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL;

ANTI-HIV AGENTS; AREA UNDER CURVE; CHILD; CONFIDENCE INTERVALS; DOSAGE FORMS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; LAMIVUDINE; LINEAR MODELS; NEVIRAPINE; PEDIATRICS; PREDICTIVE VALUE OF TESTS; STAVUDINE; TABLETS;

EID: 77952955093     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181d75e47     Document Type: Article

References (10)

1. WHO, UNAIDS, UNICEF. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector: progress report. September 2009. Available at: www.who.int/hiv/pub/towards-universal-access- report-2009.pdf. Accessed March 15, 2010.
2. L'homme RF, Kabamba D, Ewings FM, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS. 2008;22:557-565.
3. Veldkamp AI, van Heeswijk RP, Mulder JW, et al. Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine. Ther Drug Monit. 2001;23:606-611.
4. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 2000;19:453-473.
5. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
6. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet. 2001;40: 893-905.
7. Molto J, Valle M, Miranda C, et al. Once-or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. J Antimicrob Chemother. 2008;62:784-792.
8. Mulenga V, Fillekes Q, Kabamba D, et al. Pharmacokinetics of nevirapine in HIV-infected infants with body weight 3-6 kg taking pediatric fixed-dose combination tablets. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, February 8-11, 2009 (Abstract 881).
9. Oudijk JM, McIlleron H, Mulenga V, et al. Pharmacokinetics of nevirapine in young children during combined ART and rifampicin-containing antituberculosis treatment. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention Cape Twon, July 19-22, 2009 (Abstract LBPEB10).
10. Ter Heine R, Rosing H, Van Gorp EC, et al. Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrom-etry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;867:205-212.